Main objective is to investigate the tolerability of different titration schemes of BI 456906 in otherwise healthy patients with obesity/overweight, and to determine a titration scheme for future studies.

Inclusion Criteria:

• Male and female patients ≥ 18 years and < 70 years of age at screening
• Body Mass Index (BMI) ≥ 27 kg/m2 and <40 kg/m2 at screening
• A minimum absolute body weight of 70 kg at screening and a stable body weight (defined as no more than 5% change) 3 months prior to screening
• HbA1c <6.5%
• Further inclusion criteria apply

Exclusion Criteria:

• Women who are pregnant, nursing, or who plan to become pregnant while in the trial
• Supine blood pressure (BP) ≥160/100 mmHg at screening
• Major surgery (major according to the investigator's assessment) performed within 12 weeks prior to randomization or planned within 12 months after screening
• Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
• Further exclusion criteria apply

Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. Studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. Studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). Requestors can use the following link http:// trials.boehringer-ingelheim.com/ to: 1.find information in order to request access to clinical study data, for listed studies. 2.request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement'.